Around 60 per cent of colorectal cancer patients are either overdosed or underdosed with chemotherapy, causing severe side-effects that lead many to stop treatment early.
PredicTx Health, a startup founded by Professor Justin Yeung, has developed an AI algorithm that uses routine CT scans to determine body composition and patient genomics, and to calculate personalised chemotherapy doses. Early validation achieved 84 per cent accuracy – a significant improvement over the current height-and-weight-based method.
The startup has secured $1.6 million in pre-seed funding, including from the University of Melbourne Genesis Pre-Seed Fund, as well as $500,000 from the Australia's Economic Accelerator program, and is now awaiting regulatory approval. While initially focused on colorectal cancer, the technology has potential to transform chemotherapy dosing across multiple cancer types.
Key facts
- FACULTY: Faculty of Medicine, Dentistry and Health Sciences
- SECTOR: MedTech; Oncology
- YEAR FOUNDED: 2025
- STAGE: Clinical validation
- IMPACT PATHWAY: Startup
- SUSTAINABLE DEVELOPMENT GOALS ADDRESSED: Good Health and Wellbeing; Reduced Inequalities
ECOSYSTEM SUPPORT:
- $950K pre-seed funding from the Genesis Pre-Seed Fund and angel investors
- $500K Australia's Economic Accelerator Ignite grant
- $150K Victorian Government Women's Health Research Catalyst grant
- Collaborative partnership with Western Health
First published on 23 June 2026.
Share this article